KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $10.0 million.

  • Recursion Pharmaceuticals' Non Operating Income rose 27148.19% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 2981.55%. This contributed to the annual value of $14.2 million for FY2024, which is 2072.27% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Non Operating Income stood at $10.0 million for Q3 2025, which was up 27148.19% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Non Operating Income ranged from a high of $10.0 million in Q3 2025 and a low of -$11.3 million during Q1 2025
  • For the 5-year period, Recursion Pharmaceuticals' Non Operating Income averaged around $2.0 million, with its median value being $2.5 million (2024).
  • Its Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 22680000.0% in 2023, then tumbled by 36926.93% in 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Non Operating Income (Quarter) stood at $27000.0 in 2021, then soared by 12825.93% to $3.5 million in 2022, then crashed by 46.36% to $1.9 million in 2023, then surged by 160.1% to $4.9 million in 2024, then skyrocketed by 104.4% to $10.0 million in 2025.
  • Its Non Operating Income stands at $10.0 million for Q3 2025, versus $4.3 million for Q2 2025 and -$11.3 million for Q1 2025.